VLX 1570

Drug Profile

VLX 1570

Alternative Names: VLX1570

Latest Information Update: 13 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Vivolux
  • Developer Karolinska Institute; Mayo Clinic; Vivolux
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Apoptosis stimulants; Deubiquitinating enzyme inhibitors; Proteasome modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Multiple myeloma
  • Preclinical Waldenstrom's macroglobulinaemia

Most Recent Events

  • 01 Jun 2017 Vivolux suspends enrolment in a phase-I/II trial in Multiple myeloma (Combination therapy, Second-line therapy or greater) in USA and Finland (IV) (NCT02372240)
  • 08 Apr 2015 Phase-I/II clinical trials in Multiple myeloma (Combination therapy, Second-line therapy or greater) in USA, Finland (IV) (NCT02372240)
  • 07 Oct 2014 Preclinical trials in Multiple myeloma (treatment-resistant) in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top